Company Filing History:
Years Active: 2024
Title: Innovations by Marc Uknis in Hematopoietic Cell Transplantation
Introduction
Marc Uknis is an accomplished inventor based in Chadds Ford, Pennsylvania. He has made significant contributions to the field of hematopoietic cell transplantation, particularly in the prevention of graft versus host disease (GVHD). His innovative methods aim to improve patient outcomes in this critical area of medical treatment.
Latest Patents
Marc Uknis holds a patent for "Methods for reducing risk of onset of acute graft versus host disease after hematopoietic cell transplantation." This patent focuses on methods for preventing or reducing the risk of developing GVHD in patients undergoing hematopoietic cell transplantation. The disclosure details the administration of alpha-1 antitrypsin (A1AT or AAT) to patients both before and after the HCT procedure. Additionally, it outlines specific methods for treating acute GVHD (aGVHD) post-transplantation with A1AT.
Career Highlights
Marc Uknis is associated with Csl Behring Gmbh, where he continues to work on innovative solutions in the field of transplantation. His expertise and dedication to research have positioned him as a valuable contributor to advancements in medical science.
Collaborations
Marc collaborates with notable colleagues, including Christine Voigt and Gautam Baheti. Their combined efforts enhance the research and development of effective treatments in their field.
Conclusion
Marc Uknis's work in developing methods to reduce the risk of GVHD represents a significant advancement in hematopoietic cell transplantation. His contributions are vital for improving patient care and outcomes in this challenging area of medicine.